📰 Early Access Program News
Page 31 - Early Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Program. Real-time updates on events, politics, business and more.
July 19, 2022
The release note for Tesla's next iteration of FSD Beta software, FSD Beta 10.13 has been leaked online. In the release note, Tesla lists several improvements, including improvements to "Chuck Cook style unprotected left turns."
July 19, 2022
/PRNewswire/ -- Tackle.io, a software company dedicated to helping ISVs launch, grow, and scale digital routes to revenue through the clouds, has entered a...
July 19, 2022
/PRNewswire/ -- Tackle.io, a software company dedicated to helping ISVs launch, grow, and scale digital routes to revenue through the clouds, has entered a...
July 18, 2022
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions - Including a Potential Hostile Takeover of the Company - and Prevent Group from Continued Violations of Federal Securities
July 18, 2022
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid GlobeNewswire July 18, 2022 Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and...
July 14, 2022
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th
July 6, 2022
Responding to a Twitter user asking when Tesla's FSD Beta 10.13 will come out, Elon Musk has stopped shy of giving a timeline, however, says "the 3 AM oil is being burned to get this out."
June 13, 2022
Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla.
June 10, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery